Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
Presentation Material Financial Results for the Six Months Ended Janualy31,2025
Non-consolidated Financial Results for the Six Months Ended January 31, 2025 [Japanese GAAP]
StemRIM, Nov-Jan (2Q) Ordinary Profit Loss Narrows
StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms
StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy
[Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024
[Delayed]StemRIM Announces Selection for the AMED Project for Fundamental Technology Development of Regenerative Medicine and Gene Therapy
StemRIM, August-October (1Q) Ordinary Profit Loss Widens
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
StemRIM Announces Patent Registration (Europe) for the Use of Redasemtide, as a Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure
StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide
Presentation Material for Business Plan and Growth Potential
Notice Regarding Appointment of Director Candidates
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators